CSL Behring corporate brochure (English, 1.25MB)
CSL Behring corporate brochure (German, 1.25MB)
CSL Behring Global Product Portfolio (PDF, 24KB)
Interactive product pipeline
|
CSL Behring Fact Sheet
2011/12 Sales
By Region
|
| 42% | North America | | 31% | Europe | | 11% | Australia | | 9% | Asia | | 7% | Rest of World |
| CSL Behring is a world leader in the plasma protein biopharmaceuticals industry. Committed to
saving lives and improving the quality of life for people with rare and serious diseases, the company
manufactures and markets a wide range of plasma-derived and recombinant therapies worldwide. CSL Behring places its primary focus on manufacturing safe, innovative, high-quality products for
patients who rely on them to treat chronic health conditions, some of which are life-threatening. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia
and von Willebrand disease, primary immune deficiencies, certain neurological conditions, inherited
respiratory disease and hereditary angioedema. The company’s products are also used in cardiac
surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring
is a subsidiary of CSL Limited, a biopharmaceutical company headquartered in Melbourne,
Australia. For more information, visit www.cslbehring.com. |
By Theraputic Area
|
| 47% | Immunoglobulins | | 20% | Critical Care | | 15% | Plasma-derived Coagulation | | 13% | Recombinant Factor VIII | | 2% | Pulmonary Therapies | | 3% | Other |
|
| Employees................... | 9,000+ employees in 19 countries |
| Headquarters............. | King of Prussia, Pennsylvania, USA |
| Plasma Collection.... | CSL Plasma is one of the world’s largest plasma collection organizations. The company operates collection centers across the United States and Germany. Headquarters are in Boca Raton, Florida. Testing laboratories are located in the United States and Germany. |
| Manufacturing.......... | Bern, Switzerland; Marburg, Germany; and Kankakee, Illinois, USA. |
| R&D.............................. | CSL integrated R&D includes facilities in Marburg, Germany; Bern, Switzerland; King of Prussia, Pennsylvania, USA; Kankakee, Illinois, USA; Tokyo, Japan; and Broadmeadows and Parkville, Australia. |
| 2011/12 Sales.......... | Approximately U.S. $3.7 billion. |
| Therapeutic Focus | THERAPY | TREATMENT | | Immunoglobulins....... | Used for treatment of immunological disorders, such as primary immune
deficiency, idiopathic thrombocytopenic purpura, Guillain-Barré syndrome
and hemolytic disease of the newborn | | Coagulation................. | Coagulation or bleeding disorders, including hemophilia and von Willebrand
disease | | Pulmonary................... | Used for treatment of Alpha1-antitrypsin deficiency (hereditary emphysema) | | Critical Care................ | Used for treatment of hereditary angioedema and for the treatment of shock, burns and sepsis | | Wound Healing........... | Used during surgery and for wound healing | | Other............................. | Used to prevent cytomegalovirus infection in patients following solid organ
transplant |
| Media Contacts | |
|